If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Olumiant ® ▼ (baricitinib)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Olumiant Summary of Product Characteristics (SmPC)
Olumiant® ▼ (baricitinib): Laboratory Monitoring
Neutrophil, lymphocyte, hemoglobin, and hepatic transaminases levels should be assessed prior to initiation of baricitinib, and lipids should be assessed 12 weeks after initiation.
Monitoring with Baricitinib Treatment
information on laboratory monitoring with baricitinb treatment please
see Table 1.
1. Laboratory measures and monitoring guidance1
should be managed according to international clinical guidelines
weeks after initiation of treatment and thereafter according to
international clinical guidelines for hyperlipidaemia
Neutrophil Count (ANC)
should be interrupted if ANC
1 x 109 cells/L
and may be restarted once ANC return above this value
treatment initiation and thereafter according to routine patient
Lymphocyte Count (ALC)
should be interrupted if ALC
0.5 x 109 cells/L
and may be restarted once ALC return above this value
should be interrupted if Hb
8 g/dL and may be restarted once Hb return above this value
should be temporarily interrupted if drug-induced liver injury is
refer to section 4.4 of the Olumiant Summary of Product
Characteristics for further information on special warnings and
precautions for use with baricitinib.
Olumiant [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
= absolute lymphocyte count
= absolute neutrophil count
medicinal product is subject to additional monitoring. This will
allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions.
Date of Last Review:November 13, 2020
Are you satisfied with this content?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at email@example.com